New treatments of systemic lupus erythematosus
Author:
Kyttaris Vasileios C
Reference71 articles.
1. Novel evidence-based systemic lupus erythematosus responder index;Furie;Arthritis Rheum,2009
2. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response;Do;J Exp Med,2000
3. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus;Furie;Arthritis Rheum,2011
4. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial;Navarra;Lancet,2011
5. Isenberg DA, Urowitz MB, Merrill JT, Hoffman RW, Linnik MD, Morgan-Cox M, et al., editors. Efficacy and Safety of Subcutaneous Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials. American College of Rheumatology Annual Meeting; 2014; Boston, MA.